Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question

COO’s rise to top role closely follows deals designed for long-term growth, while pair of immunology drugs help offset Humira’s shortfall

Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy

On heels of ImmunoGen deal, pharma looks to Pfizer spinout led by Coles, Renaud to add neuroscience candidates nearing clinical readouts

The biopharma industry is sending drugs to Ukraine, disengaging with Russia

AbbVie's Allergan takeout adds immediate revenue but little long-term value creation